科研之友
微信
新浪微博
Facebook
分享链接
摘要
<正>引自:Yang J,et al. HLX11,a proposed pertuzumab biosimilar:Pharmacokinetics,immunogenicity,and safety profiles compared to three reference biologic products (US-,EU-,and CN-approved pertuzumab) administered to healthy male subjects[J]. BioDrugs,2022,36(3):393-409.
